Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Biotechnology

Healthcare
$2.11 +1.84%

+$0.06 today

Market cap
$235.60M
Beta
0.47
P/E (TTM)
-1.7
EPS (TTM)
-$1.87
52W Low $2.40High $5.45

Volume 2.49M

Average 3.15M

RCKT Income Before Tax

Profit after all operating and non-operating items but before income tax.

Rocket Pharmaceuticals, Inc.NASDAQ: RCKT

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$47.59M, compared with -$61.33M a year earlier. Trailing-twelve-month income before tax was -$209.38M.

Context

  • Income before tax grew in size in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near -$47.59M or moves back toward the trailing-twelve-month quarterly average of -$52.35M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$47.59M-11.9% QoQ
Last fiscal yearDec 2025
-$223.12M+13.8% YoY
LTMMar 2026
-$209.38M+18.9% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+22.4%——
1 year+13.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(223.12M) USD
Year-over-year change
+13.8%

Income Before Tax vs competitors

How RCKT compares with its peers on the latest reported figures

  • RCKT's LTM Mar 2026 income before tax of -$209.38M is the 9th highest of the 10 companies compared; the peer median is -$112.29M.
  • Its year-over-year change of +18.9% is the 2nd highest of 9, against a peer median of -20.8%.
RCKT Competitors Peer median
Income Before Tax for RCKT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
GALTGalectin Therapeutics Inc.LTM Mar 2026-$26.25M +41.9%——
LBRXLB Pharmaceuticals Inc Common StockLTM Mar 2026-$39.17M ———
DSGNDesign Therapeutics, Inc.LTM Mar 2026-$69.71M -24.0%——
QSIQuantum-Si incorporatedLTM Mar 2026-$103.9M -3.2%—5609.9%
AURAAura Biosciences, Inc.LTM Mar 2026-$112.29M -18.7%——
DBVTDBV Technologies S.A.LTM Mar 2026-$171.4M -49.3%——
SLDBSolid Biosciences Inc.LTM Mar 2026-$191.78M -37.3%——
ANNXAnnexon, Inc.LTM Mar 2026-$196.48M -17.4%——
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026-$209.38M +18.9%——
AUTLAutolus Therapeutics plcLTM Mar 2026-$288.22M -23.0%—311.3%
Peer median (excluding RCKT) -$112.29M-20.8%—2960.6%

Competitors are the stored peer set for RCKT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue000011.03M
Gross Profit0000(11.03M)
Gross Margin—————
Research & Development125.48M165.57M186.34M171.24M142.02M
Selling, General & Admin41.77M58.77M73.32M101.96M86.5M
Operating Expenses167.25M224.34M259.66M273.21M217.49M
Depreciation & Amortization5.37M6.27M7.1M9.38M11.03M
EBITDA(157.81M)(213.69M)(236.62M)(247.49M)(210.21M)
EBITDA Margin—————
Operating Income(167.25M)(224.34M)(259.66M)(273.21M)(228.52M)
Operating Margin—————
Interest Income3.07M3.89M15.94M18.22M10.62M
Interest Expense5.89M1.91M1.88M1.89M1.89M
Other Income / Expenses(1.82M)2.48M14.06M14.46M5.39M
Income Before Tax(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(169.07M)(221.86M)(245.6M)(258.75M)(223.12M)
Net Margin—————
EPS (Basic)(2.68)(3.26)(2.92)(2.73)(2.01)
EPS (Diluted)(2.68)(3.26)(2.92)(2.73)(2.01)
Weighted Avg Shares63.24M68.15M84.01M94.81M111.12M
Weighted Avg Shares (Diluted)63.24M68.15M84.01M94.81M111.12M

Rocket Pharmaceuticals, Inc.

NASDAQ:RCKT

Intrinsic Alpha fair value

Locked

Current Price

$2.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.